Mortality-Related Risk Factors and Novel Antimicrobial Regimens for Carbapenem-Resistant Enterobacteriaceae Infections: A Systematic Review

References

• Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America guidance on the treatment of Extended-spectrum beta-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis. 2021;72(7):e169–e183. doi:10.1093/cid/ciaa1478
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention Facility. Guidance for control of carbapenem resistant Enterobacteriaceae (CRE)ō; 2015. Available from: https://www.cdc.gov/hai/organisms/cre/. Accessed November 22, 2022.
   Google Scholar
• Suay-García B, Pérez-Gracia MT. Present and future of carbapenem-resistant Enterobacteriaceae (CRE) infections. Antibiotics. 2019;8(3):122. doi:10.3390/antibiotics8030122
   Web of Science ®Google Scholar
• Han R, Shi Q, Wu S, et al. Dissemination of carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) among carbapenem-resistant Enterobacteriaceae isolated from adult and children patients in China. Front Cell Infect Microbiol. 2020;10:314. doi:10.3389/fcimb.2020.00314
   PubMed Web of Science ®Google Scholar
• Campos AC, Albiero J, Ecker AB, et al. Outbreak of Klebsiella pneumoniae carbapenemase-producing K pneumoniae: a systematic review. Am J Infect Control. 2016;44(11):1374–1380. doi:10.1016/j.ajic.2016.03.022
   PubMed Web of Science ®Google Scholar
• Trecarichi EM, Tumbarello M. Therapeutic options for carbapenem-resistant Enterobacteriaceae infections. Virulence. 2017;8(4):470–484. doi:10.1080/21505594.2017.1292196
   PubMed Web of Science ®Google Scholar
• Durante-Mangoni E, Andini R, Zampino R. Management of carbapenem-resistant Enterobacteriaceae infections. Clin Microbiol Infect. 2019;25(8):943–950. doi:10.1016/j.cmi.2019.04.013
   PubMed Web of Science ®Google Scholar
• Soontaros S, Leelakanok N. Association between carbapenem-resistant Enterobacteriaceae and death: a systematic review and meta-analysis. Am J Infect Control. 2019;47(10):1200–1212. doi:10.1016/j.ajic.2019.03.020
   Web of Science ®Google Scholar
• Falcone M, Tiseo G, Antonelli A, et al. Clinical features and outcomes of bloodstream infections caused by New Delhi metallo-β-lactamase-producing Enterobacterales during a regional outbreak. Open Forum Infect Dis. 2020;7(2):ofaa011. doi:10.1093/ofid/ofaa011
   Web of Science ®Google Scholar
• Xu L, Sun X, Ma X. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae. Ann Clin Microbiol Antimicrob. 2017;16(1):18. doi:10.1186/s12941-017-0191-3
   PubMed Web of Science ®Google Scholar
• Chen L, Han X, Li Y, et al. Assessment of mortality-related risk factors and effective antimicrobial regimens for treatment of bloodstream infections caused by carbapenem-resistant Enterobacterales. Antimicrob Agents Chemother. 2021;65(9):e0069821. doi:10.1128/AAC.00698-21
   PubMed Web of Science ®Google Scholar
• Zuo Y, Zhao D, Song G, et al. Risk factors, molecular epidemiology, and outcomes of carbapenem-resistant Klebsiella pneumoniae infection for hospital-acquired pneumonia: a matched case-control study in Eastern China during 2015–2017. Microb Drug Resist. 2021;27(2):204–211. doi:10.1089/mdr.2020.0162
   PubMed Web of Science ®Google Scholar
• Shen L, Lian C, Zhu B, et al. Bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae: a single-center retrospective study on risk factors and therapy options. Microb Drug Resist. 2021;27(2):227–233. doi:10.1089/mdr.2019.0455
   Web of Science ®Google Scholar
• Seo H, Lee SC, Chung H, et al. Clinical and microbiological analysis of risk factors for mortality in patients with carbapenem-resistant Enterobacteriaceae bacteremia. Int J Antimicrob Agents. 2020;56(4):106126. doi:10.1016/j.ijantimicag.2020.106126
   PubMed Web of Science ®Google Scholar
• Palacios-Baena ZR, Giannella M, Manissero D, et al. Risk factors for carbapenem-resistant Gram-negative bacterial infections: a systematic review. Clin Microbiol Infect. 2021;27(2):228–235. doi:10.1016/j.cmi.2020.10.016
   PubMed Web of Science ®Google Scholar
• Qian Y, Bi Y, Liu S, et al. Predictors of mortality in patients with carbapenem-resistant Klebsiella pneumoniae infection: a meta-analysis and a systematic review. Ann Palliat Med. 2021;10(7):7340–7350. doi:10.21037/apm-21-338
   PubMed Web of Science ®Google Scholar
• Paul M, Carrara E, Retamar P, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect. 2022;28(4):521–547. doi:10.1016/j.cmi.2021.11.025
   PubMed Web of Science ®Google Scholar
• Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, et al. Treatment of infections caused by Extended-spectrum-beta-lactamase-, ampc-, and carbapenemase-producing Enterobacteriaceae. Clin Microbiol Rev. 2018;31(2). doi:10.1128/CMR.00079-17
   PubMed Web of Science ®Google Scholar
• Palacios-Baena ZR, Oteo J, Conejo C, et al. Comprehensive clinical and epidemiological assessment of colonisation and infection due to carbapenemase-producing Enterobacteriaceae in Spain. J Infect. 2016;72(2):152–160. doi:10.1016/j.jinf.2015.10.008
   PubMed Web of Science ®Google Scholar
• Lin YT, Chuang C, Su CF, et al. Efficacy of appropriate antimicrobial therapy on the survival of patients with carbapenem nonsusceptible Klebsiella pneumoniae infection: a multicenter study in Taiwan. Medicine. 2015;94(33):e1405. doi:10.1097/MD.0000000000001405
   Web of Science ®Google Scholar
• Fang J, Li H, Zhang M, et al. Efficacy of ceftazidime-avibactam versus polymyxin B and risk factors affecting clinical outcomes in patients with carbapenem-resistant Klebsiella pneumoniae infections a retrospective study. Front Pharmacol. 2021;12:780940. doi:10.3389/fphar.2021.780940
   PubMed Web of Science ®Google Scholar
• Andrey DO, Pereira Dantas P, Martins WBS, et al. An emerging clone, Klebsiella pneumoniae carbapenemase 2-producing K. pneumoniae sequence type 16, associated with high mortality rates in a CC258-endemic setting. Clin Infect Dis. 2020;71(7):e141–e150. doi:10.1093/cid/ciz1095
   PubMed Web of Science ®Google Scholar
• Chotiprasitsakul D, Srichatrapimuk S, Kirdlarp S, et al. Epidemiology of carbapenem-resistant Enterobacteriaceae: a 5-year experience at a tertiary care hospital. Infect Drug Resist. 2019;12:461–468. doi:10.2147/IDR.S192540
   Web of Science ®Google Scholar
• Cristina ML, Alicino C, Sartini M, et al. Epidemiology, management, and outcome of carbapenem-resistant Klebsiella pneumoniae bloodstream infections in hospitals within the same endemic metropolitan area. J Infect Public Health. 2018;11(2):171–177. doi:10.1016/j.jiph.2017.06.003
   PubMed Web of Science ®Google Scholar
• Li Y, Li J, Hu T, et al. Five-year change of prevalence and risk factors for infection and mortality of carbapenem-resistant Klebsiella pneumoniae bloodstream infection in a tertiary hospital in North China. Antimicrob Resist Infect Control. 2020;9(1):79. doi:10.1186/s13756-020-00728-3
   PubMed Web of Science ®Google Scholar
• Capone A, Giannella M, Fortini D, et al. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect. 2013;19(1):E23–E30. doi:10.1111/1469-0691.12070
   PubMed Web of Science ®Google Scholar
• Geng TT, Xu X, Huang M. High-dose tigecycline for the treatment of nosocomial carbapenem-resistant Klebsiella pneumoniae bloodstream infections: a retrospective cohort study. Medicine. 2018;97(8):e9961. doi:10.1097/MD.0000000000009961
   PubMed Web of Science ®Google Scholar
• Rivera-Espinar F, Machuca I, Tejero R, et al. Impact of KPC production and high-level meropenem resistance on all-cause mortality of ventilator-associated pneumonia in association with Klebsiella pneumoniae. Antimicrob Agents Chemother. 2020;64(6):e02164. doi:10.1128/AAC.02164-19
   Web of Science ®Google Scholar
• Tumbarello M, Trecarichi EM, De Rosa FG, et al. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother. 2015;70(7):2133–2143. doi:10.1093/jac/dkv086
   PubMed Web of Science ®Google Scholar
• Mora-Guzman I, Rubio-Perez I, Domingo-Garcia D, et al. Intra-abdominal infections by carbapenemase-producing Enterobacteriaceae in a surgical unit: counting mortality, stay, and costs. Surg Infect. 2021;22(3):266–273. doi:10.1089/sur.2020.137
   Web of Science ®Google Scholar
• Falcone M, Russo A, Iacovelli A, et al. Predictors of outcome in ICU patients with septic shock caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Clin Microbiol Infect. 2016;22(5):444–450. doi:10.1016/j.cmi.2016.01.016
   PubMed Web of Science ®Google Scholar
• Wang X, Wang Q, Cao B, et al. Retrospective observational study from a Chinese network of the impact of combination therapy versus monotherapy on mortality from carbapenem-resistant Enterobacteriaceae bacteremia. Antimicrob Agents Chemother. 2019;63(1):e01511. doi:10.1128/AAC.01511-18
   PubMed Web of Science ®Google Scholar
• Zhang H, Guo Z, Chai Y, et al. Risk factors for and clinical outcomes of carbapenem-resistant Klebsiella pneumoniae nosocomial infections: a retrospective study in a tertiary hospital in Beijing, China. Infect Drug Resist. 2021;14:1393–1401. doi:10.2147/IDR.S298530
   PubMed Web of Science ®Google Scholar
• Bar-Yoseph H, Cohen N, Korytny A, et al. Risk factors for mortality among carbapenem-resistant Enterobacteriaceae carriers with focus on immunosuppression. J Infect. 2019;78(2):101–105. doi:10.1016/j.jinf.2018.10.003
   Web of Science ®Google Scholar
• Tuon FF, Graf ME, Merlini A, et al. Risk factors for mortality in patients with ventilator-associated pneumonia caused by carbapenem-resistant Enterobacteriaceae. Braz J Infect Dis. 2017;21(1):1–6. doi:10.1016/j.bjid.2016.09.008
   Web of Science ®Google Scholar
• Liu KS, Tong YS, Lee MT, et al. Risk factors of 30-day all-cause mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection. J Pers Med. 2021;11(7):616. doi:10.3390/jpm11070616
   PubMed Web of Science ®Google Scholar
• Lim FK, Liew YX, Cai Y, et al. Treatment and outcomes of infections caused by diverse carbapenemase-producing carbapenem-resistant Enterobacterales. Front Cell Infect Microbiol. 2020;10:579462. doi:10.3389/fcimb.2020.579462
   Web of Science ®Google Scholar
• Li C, Li Y, Zhao Z, et al. Treatment options and clinical outcomes for carbapenem-resistant Enterobacteriaceae bloodstream infection in a Chinese university hospital. J Infect Public Health. 2019;12(1):26–31. doi:10.1016/j.jiph.2018.08.002
   PubMed Web of Science ®Google Scholar
• Lee NY, Tsai CS, Syue LS, et al. Treatment outcome of bacteremia due to non-carbapenemase-producing carbapenem-resistant Klebsiella pneumoniae bacteremia: role of carbapenem combination therapy. Clin Ther. 2020;42(3):e33–e44. doi:10.1016/j.clinthera.2020.01.004
   Web of Science ®Google Scholar
• Su CF, Chuang C, Lin YT, et al. Treatment outcome of non-carbapenemase-producing carbapenem-resistant Klebsiella pneumoniae infections: a multicenter study in Taiwan. Eur J Clin Microbiol Infect Dis. 2018;37(4):651–659. doi:10.1007/s10096-017-3156-8
   PubMed Web of Science ®Google Scholar
• Lin YT, Su CF, Chuang C, et al. Appropriate treatment for bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae and Escherichia coli: a nationwide multicenter study in Taiwan. Open Forum Infect Dis. 2019;6(2):ofy336. doi:10.1093/ofid/ofy336
   Web of Science ®Google Scholar
• Di Domenico EG, Cavallo I, Sivori F, et al. Biofilm production by carbapenem-resistant Klebsiella pneumoniae significantly increases the risk of death in oncological patients. Front Cell Infect Microbiol. 2020;10:561741. doi:10.3389/fcimb.2020.561741
   Web of Science ®Google Scholar
• Balkan II, Aygun G, Aydin S, et al. Blood stream infections due to OXA-48-like carbapenemase-producing Enterobacteriaceae: treatment and survival. Int J Infect Dis. 2014;26:51–56. doi:10.1016/j.ijid.2014.05.012
   PubMed Web of Science ®Google Scholar
• Zhou C, Jin L, Wang Q, et al. Bloodstream infections caused by carbapenem-resistant Enterobacterales: risk factors for mortality, antimicrobial therapy and treatment outcomes from a prospective multicenter study. Infect Drug Resist. 2021;14:731–742. doi:10.2147/IDR.S294282
   PubMed Web of Science ®Google Scholar
• Tian X, Huang C, Ye X, et al. Carbapenem-resistant Enterobacter cloacae causing nosocomial infections in southwestern China: molecular epidemiology, risk factors, and predictors of mortality. Infect Drug Resist. 2020;13:129–137. doi:10.2147/IDR.S234678
   Web of Science ®Google Scholar
• Brescini L, Morroni G, Valeriani C, et al. Clinical and epidemiological characteristics of KPC-producing Klebsiella pneumoniae from bloodstream infections in a tertiary referral center in Italy. BMC Infect Dis. 2019;19(1):611. doi:10.1186/s12879-019-4268-9
   PubMed Web of Science ®Google Scholar
• Chang YY, Chuang YC, Siu LK, et al. Clinical features of patients with carbapenem nonsusceptible Klebsiella pneumoniae and Escherichia coli in intensive care units: a nationwide multicenter study in Taiwan. J Microbiol Immunol Infect. 2015;48(2):219–225. doi:10.1016/j.jmii.2014.05.010
   PubMedGoogle Scholar
• Navarro-san francisco C, Mora-Rillo M, Romero-Gómez MP, et al. Bacteraemia due to OXA-48-carbapenemase-producing Enterobacteriaceae: a major clinical challenge. Clin Microbiol Infect. 2013;19(2):E72–E79. doi:10.1111/1469-0691.12091
   PubMed Web of Science ®Google Scholar
• Zheng G, Zhang J, Wang B, et al. Ceftazidime-avibactam in combination with in vitro non-susceptible antimicrobials versus ceftazidime-avibactam in monotherapy in critically ill patients with carbapenem-resistant Klebsiella pneumoniae infection: a retrospective cohort study. Infect Dis Ther. 2021;10(3):1699–1713. doi:10.1007/s40121-021-00479-7
   PubMed Web of Science ®Google Scholar
• Gu J, Xu J, Zuo TT, et al. Ceftazidime-avibactam in the treatment of infections from carbapenem-resistant Klebsiella pneumoniae: ceftazidime-avibactam against CR-KP infections. J Glob Antimicrob Resist. 2021;26:20–25. doi:10.1016/j.jgar.2021.04.022
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Raffaelli F, Giannella M, et al. Ceftazidime-avibactam use for Klebsiella pneumoniae carbapenemase-producing K. Pneumoniae infections: a retrospective observational multicenter study. Clin Infect Dis. 2021;73(9):1664–1676. doi:10.1093/cid/ciab176
   PubMed Web of Science ®Google Scholar
• Villegas MV, Pallares CJ, Escandon-Vargas K, et al. Characterization and clinical impact of bloodstream infection caused by carbapenemase-producing Enterobacteriaceae in seven Latin American countries. PLoS One. 2016;11(4):e0154092. doi:10.1371/journal.pone.0154092
   PubMed Web of Science ®Google Scholar
• Van Duin D, Lok JJ, Earley M, et al. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis. 2018;66(2):163–171. doi:10.1093/cid/cix783
   PubMed Web of Science ®Google Scholar
• Medeiros GS, Rigatto MH, Falci DR, et al. Combination therapy with polymyxin B for carbapenemase-producing Klebsiella pneumoniae bloodstream infection. Int J Antimicrob Agents. 2019;53(2):152–157. doi:10.1016/j.ijantimicag.2018.10.010
   PubMed Web of Science ®Google Scholar
• De Pascale G, Martucci G, Montini L, et al. Double carbapenem as a rescue strategy for the treatment of severe carbapenemase-producing Klebsiella pneumoniae infections: a two-center, matched case-control study. Crit Care. 2017;21(1):173. doi:10.1186/s13054-017-1769-z
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis. 2017;17(7):726–734. doi:10.1016/S1473-3099(17)30228-1
   PubMed Web of Science ®Google Scholar
• Giannella M, Trecarichi EM, Giacobbe DR, et al. Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection. Int J Antimicrob Agents. 2018;51(2):244–248. doi:10.1016/j.ijantimicag.2017.08.019
   PubMed Web of Science ®Google Scholar
• Sousa A, Perez-Rodriguez MT, Soto A, et al. Effectiveness of ceftazidime/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother. 2018;73(11):3170–3175. doi:10.1093/jac/dky295
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Trecarichi EM, Corona A, et al. Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Clin Infect Dis. 2019;68(3):355–364. doi:10.1093/cid/ciy492
   PubMed Web of Science ®Google Scholar
• de Oliveira MS, de Assis DB, Freire MP, et al. Treatment of KPC-producing Enterobacteriaceae: suboptimal efficacy of polymyxins. Clin Microbiol Infect. 2015;21(2):e1–e7. doi:10.1016/j.cmi.2014.07.010
   PubMed Web of Science ®Google Scholar
• King M, Heil E, Kuriakose S, et al. Multicenter study of outcomes with ceftazidime-avibactam in patients with carbapenem-resistant Enterobacteriaceae infections. Antimicrob Agents Chemother. 2017;61(7):e00449. doi:10.1128/AAC.00449-17
   PubMed Web of Science ®Google Scholar
• Satlin MJ, Chen L, Gomez-Simmonds A, et al. Impact of a rapid molecular test for Klebsiella pneumoniae carbapenemase and ceftazidime-avibactam use on outcomes after bacteremia caused by carbapenem-resistant Enterobacterales. Clin Infect Dis. 2022;ciac354. doi:10.1093/cid/ciac354
   Web of Science ®Google Scholar
• Chen J, Yang Y, Yao H, et al. Prediction of prognosis in adult patients with carbapenem-resistant Klebsiella pneumoniae infection. Front Cell Infect Microbiol. 2021;11:818308. doi:10.3389/fcimb.2021.818308
   Web of Science ®Google Scholar
• Fritzenwanker M, Imirzalioglu C, Herold S, et al. Treatment options for carbapenem- resistant Gram-negative infections. Dtsch Arztebl Int. 2018;115(20–21):345–352. doi:10.3238/arztebl.2018.0345
   PubMed Web of Science ®Google Scholar
• Shields RK, Clancy CJ, Press EG, et al. Aminoglycosides for treatment of bacteremia due to carbapenem-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother. 2016;60(5):3187–3192. doi:10.1128/AAC.02638-15
   Web of Science ®Google Scholar
• Dubrovskaya Y, Chen TY, Scipione MR, et al. Risk factors for treatment failure of polymyxin B monotherapy for carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother. 2013;57(11):5394–5397. doi:10.1128/AAC.00510-13
   PubMed Web of Science ®Google Scholar
• Yu L, Zhang J, Fu Y, et al. Synergetic effects of combined treatment of colistin with meropenem or amikacin on carbapenem-resistant Klebsiella pneumoniae in vitro. Front Cell Infect Microbiol. 2019;9:422. doi:10.3389/fcimb.2019.00422
   Web of Science ®Google Scholar
• Ni W, Yang D, Guan J, et al. In vitro and in vivo synergistic effects of tigecycline combined with aminoglycosides on carbapenem-resistant Klebsiella pneumoniae. J Antimicrob Chemother. 2021;76(8):2097–2105. doi:10.1093/jac/dkab122
   Web of Science ®Google Scholar
• Freire MP, de Oliveira Garcia D, Cury AP, et al. The role of therapy with aminoglycoside in the outcomes of kidney transplant recipients infected with polymyxin- and carbapenem-resistant Enterobacteriaceae. Eur J Clin Microbiol Infect Dis. 2019;38(4):755–765. doi:10.1007/s10096-019-03468-4
   PubMed Web of Science ®Google Scholar
• van Duin D, Cober E, Richter SS, et al. Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniae. J Antimicrob Chemother. 2015;70(4):1203–1211. doi:10.1093/jac/dku495
   PubMed Web of Science ®Google Scholar
• Cancelli F, Oliva A, De Angelis M, et al. Role of double-carbapenem regimen in the treatment of infections due to carbapenemase producing carbapenem-resistant Enterobacteriaceae: a single-center, observational study. Biomed Res Int. 2018;2018:2785696. doi:10.1155/2018/2785696
   PubMed Web of Science ®Google Scholar
• Del Bono V, Giacobbe DR, Marchese A, et al. Meropenem for treating kpc-producing Klebsiella pneumoniae bloodstream infections: should we get to the pk/pd root of the paradox? Virulence. 2017;8(1):66–73. doi:10.1080/21505594.2016.1213476
   PubMed Web of Science ®Google Scholar
• Pea F, Della Siega P, Cojutti P, et al. Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae? Int J Antimicrob Agents. 2017;49(2):255–258. doi:10.1016/j.ijantimicag.2016.10.018
   PubMed Web of Science ®Google Scholar
• Cojutti P, Sartor A, Righi E, et al. Population pharmacokinetics of high-dose continuous-infusion meropenem and considerations for use in the treatment of infections due to KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2017;61(10):e00794. doi:10.1128/AAC.00794-17
   Web of Science ®Google Scholar
• Dietl B, Martínez LM, Calbo E, et al. Update on the role of ceftazidime-avibactam in the management of carbapenemase-producing Enterobacterales. Future Microbiol. 2020;15:473–484. doi:10.2217/fmb-2020-0012
   PubMed Web of Science ®Google Scholar
• Agyeman AA, Bergen PJ, Rao GG, et al. A systematic review and meta-analysis of treatment outcomes following antibiotic therapy among patients with carbapenem-resistant Klebsiella pneumoniae infections. Int J Antimicrob Agents. 2020;55(1):105833. doi:10.1016/j.ijantimicag.2019.10.014
   PubMed Web of Science ®Google Scholar
• Du X, Xu X, Yao J, et al. Predictors of mortality in patients infected with carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis. Am J Infect Control. 2019;47(9):1140–1145. doi:10.1016/j.ajic.2019.03.003
   PubMed Web of Science ®Google Scholar
• Cienfuegos-Gallet AV, Ocampo de Los Ríos AM, Sierra VP, et al. Risk factors and survival of patients infected with carbapenem-resistant Klebsiella pneumoniae in a KPC endemic setting: a case-control and cohort study. BMC Infect Dis. 2019;19(1):830. doi:10.1186/s12879-019-4461-x
   PubMed Web of Science ®Google Scholar
• Wilson AP, Livermore DM, Otter JA, et al. Prevention and control of multi-drug-resistant Gram-negative bacteria: recommendations from a Joint Working Party. J Hosp Infect. 2016;92(Suppl 1):S1–S44. doi:10.1016/j.jhin.2015.08.007
   PubMed Web of Science ®Google Scholar
• Falagas ME, Lourida P, Poulikakos P, et al. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother. 2014;58(2):654–663. doi:10.1128/AAC.01222-13
   PubMed Web of Science ®Google Scholar
• Jacobs M, Grégoire N, Mégarbane B, et al. Population pharmacokinetics of colistin methanesulfonate and colistin in critically ill patients with acute renal failure requiring intermittent hemodialysis. Antimicrob Agents Chemother. 2016;60(3):1788–1793. doi:10.1128/AAC.01868-15
   Web of Science ®Google Scholar
• Doi Y. Treatment options for carbapenem-resistant Gram-negative bacterial infections. Clin Infect Dis. 2019;69(Suppl 7):S565–S575. doi:10.1093/cid/ciz830
   PubMed Web of Science ®Google Scholar
• Ackley R, Roshdy D, Meredith J, et al. Meropenem-vaborbactam versus ceftazidime-avibactam for treatment of carbapenem-resistant Enterobacteriaceae infections. Antimicrob Agents Chemother. 2020;64(5):e02313. doi:10.1128/AAC.02313-19
   PubMed Web of Science ®Google Scholar
• Fiore M, Alfieri A, Di Franco S, et al. Ceftazidime-avibactam combination therapy compared to ceftazidime-avibactam monotherapy for the treatment of severe infections due to carbapenem-resistant pathogens: a systematic review and network meta-analysis. Antibiotics. 2020;9(7):338. doi:10.3390/antibiotics9070388
   Web of Science ®Google Scholar
• Onorato L, Di Caprio G, Signoriello S, et al. Efficacy of ceftazidime/avibactam in monotherapy or combination therapy against carbapenem-resistant Gram-negative bacteria: a meta-analysis. Int J Antimicrob Agents. 2019;54(6):735–740. doi:10.1016/j.ijantimicag.2019.08.025
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang J, Wang R, et al. Resistance to ceftazidime-avibactam and underlying mechanisms. J Glob Antimicrob Resist. 2020;22:18–27. doi:10.1016/j.jgar.2019.12.009
   PubMed Web of Science ®Google Scholar